Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients

Xiangqian Zheng1, Chen Peng2, Ming Gao1, Jingtai Zhi1, Xiukun Hou1, Jingzhu Zhao1, Xi Wei3, Jiadong Chi1, Dapeng Li1, Biyun Qian4

1Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China; 2Department of Head and Neck, Shanxi Cancer Hospital, Taiyuan 030013, China; 3Department of Ultrasound, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China; 4Department of Epidemiology, School of Public Health, Shanghai Jiao Tong University, Shanghai 200240, China

ABSTRACT

Objective: The purposes of this study were to identify risk factors for cervical lymph node metastasis and to examine the association between \textit{BRAF}^{V600E} status and clinical features in papillary thyroid microcarcinoma (PTMC).

Methods: A total of 1,587 patients with PTMC, treated in Tianjin Medical University Cancer Institute and Hospital from January 2011 to March 2013, underwent retrospective analysis. We reviewed and analyzed factors including clinical results, pathology records, ultrasound results, and \textit{BRAF}^{V600E} status.

Results: Multivariate logistic regression analyses demonstrated that gender (male) \( \text{OR} = 1.845, P = 0.000 \), age (< 45 years) \( \text{OR} = 1.606, P = 0.000 \), tumor size (> 6 mm) \( \text{OR} = 2.137, P = 0.000 \), bilateralism \( \text{OR} = 2.011, P = 0.000 \) and extrathyroidal extension \( \text{OR} = 1.555, P = 0.001 \) served as independent predictors of central lymph node metastasis (CLNM). Moreover, CLNM \( \text{OR} = 29.354, P = 0.000 \) served as an independent predictor of lateral lymph node metastasis (LLNM). Among patients with a solitary primary tumor, those with tumor location in the lower third of the thyroid lobe or the isthmus were more likely to experience CLNM \( P < 0.05 \). Univariate analyses indicated that CLNM, LLNM, extrathyroidal extension, and multifocality were not significantly associated with \textit{BRAF}^{V600E} mutation.

Conclusions: The present study suggested that prophylactic neck dissection of the central compartment should be considered in patients with PTMC, particularly in men with tumor size greater than 6 mm, age less than 45 years, extrathyroidal extension, and tumor bilaterality. Among patients with PTMC, \textit{BRAF}^{V600E} mutation is not significantly associated with prognostic factors. For a better understanding of surgical management of PTMC and the risk factors, we recommend multicenter research and long-term follow-up.

KEYWORDS

PTMC; risk factors; CLNM; LLNM; \textit{BRAF}^{V600E} mutation

Introduction

Papillary thyroid microcarcinoma (PTMC) is defined by the World Health Organization (WHO) as a papillary thyroid carcinoma (PTC) \( \leq 1 \text{ cm} \). Clinically, fine needle aspiration biopsy (FNAB) and ultrasonography (US) are utilized to detect PTMC in patients without palpable thyroid nodes. Although PTMC has an indolent course, many cases have demonstrated highly aggressive clinical features, such as extrathyroidal extension and cervical lymph node metastasis. The incidences of central lymph node metastasis (CLNM) (24.1%–64.1%) and lateral lymph node metastasis (LLNM) (3.7%–44.5%) for PTMC are comparable with those of PTC.

\textit{BRAF} mutation is a common genetic alternation in thyroid carcinoma. The most common and typical mutation in the \textit{BRAF} gene is T1779A in exon 15, which results in a V600E amino acid substitution. However, controversial results have been observed in studies of PTMC, as some research has shown that \textit{BRAF}^{V600E} mutation in PTMC led to more aggressive behavior, whereas other studies found that the \textit{BRAF}^{V600E} mutation was not significantly related to high-risk clinicopathologic characteristics.
As the clinical features of PTMC and the risk factors for CLNM have been previously investigated\textsuperscript{10-13}, the aim of the present study was to examine the risk factors for lymph node metastasis, including both CLNM and LLNM, based on US results and postoperative pathological records in the setting of a large cohort of Chinese patients with PTMC.

**Materials and methods**

**Patients**

A total of 3,789 patients with PTC were initially treated at Tianjin Medical University Cancer Institute and Hospital from January 2011 to March 2013. Among these patients, 1,587 were diagnosed with PTMC based on postoperative pathology.

All patients underwent indirect laryngoscopy before and after surgery. Preoperative US, performed in all cases, provided information regarding disease and possible cervical LNM. When preoperative findings were suspicious for LNM, computed tomography (CT) was performed. Preoperative FNAB was not performed routinely in patients with PTMC. Primary thyroid tumor location was divided into four regions: upper third, middle third, lower third, or isthmus, according to US imaging results.

Different therapeutic strategies were used for different types of PTMC, such as lobectomy with isthmectomy plus ipsilateral central lymph node dissection (CLND) for unilateral PTMC, isthmectomy plus prophylactic bilateral CLND for isthmus PTMC, and near-total thyroidectomy plus bilateral CLND for multiple tumors limited to a single thyroid lobe. Moreover, patients with multiple bilateral tumors were treated with total thyroidectomy with bilateral CLND, and patients with US and CT findings suspicious for LLNM were treated with ipsilateral lateral lymph node dissection, including levels II-V. Surgical treatments for the 1,587 patients are shown in Table 1.

Extrathyroidal extension, tumor size, tumor number, and presence of LLNM and CLNM were confirmed by two pathologists independently in a blinded fashion. Cases in which findings were inconsistent were discussed with a third pathologist. Extrathyroidal extension was defined according to gross infiltration evident at the time of surgery or by microscopic evidence on pathologic examination. Multifocality was defined as the presence of more than one tumor lesion in the thyroid. The maximum diameter of the primary tumor was defined as tumor size in multifocal cases.

Postoperative complications were also evaluated. Temporary hypoparathyroidism was defined as serum calcium < 8 mg/dL within 6 months after surgery. Permanent hypoparathyroidism was defined as low calcium levels in a patient with low/absent parathyroid hormone levels 6 months after surgery. Vocal cord paralysis was defined as temporary recurrent laryngeal nerve injury within 6 months after the operation; vocal cord paralysis continuing longer than 6 months was defined as permanent laryngeal nerve injury.

Follow-up data were available for all 1,587 patients, and the follow-up period ranged from 40 to 72 months. All patients underwent US every 3–6 months in our hospital during follow-up. This retrospective study was approved by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital.

**DNA extraction and analysis of BRAF\textsuperscript{V600E} mutation**

DNA was extracted from paraffin-embedded tissues using a kit (Tiangen, Beijing, China) according to the manufacturer’s instructions. Specifically, we selected unstained tumor tissue areas on 2 mm thick sections for comparison to hematoxylin and eosin-stained sections. For small tumors, we adopted laser-capture microdissection to collect tissues. Tumor samples were incubated in TE9 for 2 days at 37°C, with fresh proteinase K added daily. Samples were then centrifuged, and the supernatants were digested for an additional 2 days at 55°C. Chelex 100 resin (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was added to each sample and incubated for 1 h, after which the supernatant was removed. DNA was extracted using phenol-chloroform, concentrated using ethanol precipitation, and resuspended in Tris-EDTA (1 mM EDTA and 10 mM Tris hydrochloride; pH 8.0).

**Table 1** Surgical treatment in 1,587 patients

| Treatment                              | n (%)  |
|----------------------------------------|--------|
| **Thyroid surgery**                    |        |
| Lobectomy with isthmectomy             | 987 (62.2) |
| Isthmectomy                            | 27 (1.7) |
| Near-total thyroidectomy               | 195 (12.3) |
| Total thyroidectomy                    | 378 (23.8) |
| **Lymph node dissection**              |        |
| Ipsilateral central lymph node dissection | 974 (61.4) |
| Bilateral central lymph node dissection | 613 (38.6) |
| Ipsilateral lateral lymph node dissection | 98 (6.2) |
| No resection                           | 0      |
The DNA samples extracted from tissues were then subjected to PCR analysis to explore the \textit{BRAF}^{V600E} mutation. The appropriate primers have been described in previous research\textsuperscript{33}. PCR cycles were performed using the BigDye Terminator sequencing kit (Applied Biosystems, Foster City, CA, USA) and the sequencing products were analyzed with an ABI PRISM 310 Genetic Analyzer (Applied Biosystems).

\textbf{Statistical analysis}

SPSS 22.0 software (IBM Corp., Version 22.0, Armonk, NY, USA) was used to analyze the data. Data were presented as mean ± standard deviation. The $\chi^2$ test or Fisher’s exact test was used to compare cervical LNM and \textit{BRAF}^{V600E} mutation status with clinicopathologic features. We performed multivariate logistic regression analysis to assess independent risk factors for cervical LNM, using the factors screened by univariate analysis, with $P < 0.05$. We employed receiver operating characteristic curve (ROC) analysis to determine the optimal cutoff point of primary tumor size for determining the risk of CLNM. Values of $P < 0.05$ were considered statistically significant.

\textbf{Results}

\textbf{Patient characteristics}

There were 1,587 patients with PTMC, consisting of 1,251 (78.8\%) women and 336 (21.2\%) men. The mean age was 45.7 (11 to 73) years, and 333 (21.0\%) patients were diagnosed with Hashimoto’s thyroiditis.

The mean size of primary tumors in the largest diameter was 5.9 ± 2.5 mm, with 586 (36.9\%) tumors larger than 6 mm and 1,001 (63.1\%) tumors smaller than or equal to 6 mm in diameter. Among all patients, 1,039 (65.5\%) and 573 (36.1\%) demonstrated extrathyroidal extension and multifocality, respectively. Considering solitary lesions, 312 (30.8\%) were in the upper third of the lobe, 268 (26.4\%) were in the middle third, 407 (40.1\%) were in the lower third, and 27 (2.7\%) were in the isthmus.

CLNM occurred in 491 (30.9\%) of the 1,587 patients, while LLNM was found in 73 (4.6\%). Skip metastases, meaning LLNM without CLNM, were observed in 19 patients (1.2\%). Table 2 shows the clinical and pathologic characteristics of these patients.

\textbf{Risk factors for CLNM}

ROC curve analysis showed that primary tumor size of 6 mm was the optimal cutoff point to distinguish between patients with and without CLNM (area = 0.649, standard error = 0.015, asymptotic significance = 0.000, 95\% confidence interval = 0.620–0.678).

Risk factors for CLNM were evaluated by univariate and multivariate analyses according to final pathological results. In univariate analysis, male gender, age < 45 years, primary tumor size greater than 6 mm, multifocality, bilateralism, and extrathyroidal extension ($P < 0.01$) were significantly related to CLNM. Moreover, univariate analysis performed for the solitary primary tumor group showed that CLNM was significantly associated with tumor location ($P < 0.05$); tumors located in the lower third and isthmus conferred a higher risk of CLNM than did those in the upper third. On multivariate analysis, male gender [odds ratio (OR) = 1.845, $P = 0.000$], age < 45 (OR = 1.606, $P = 0.000$), tumor size greater than 6 mm (OR = 2.137, $P = 0.000$), bilateralism (OR = 2.011, $P = 0.000$), and extrathyroidal extension (OR = 1.555, $P = 0.001$) were independent risk factors for CLNM, and number of primary tumors was not significantly correlated with CLNM ($P > 0.05$) (Table 3).

\textbf{Risk factors for LLNM}

According to univariate analysis, tumor size greater than 6 mm, CLNM, extrathyroidal extension, multifocality, bilateralism, and tumor location ($P < 0.05$) were characterized as risk factors for LLNM, whereas sex, age, and Hashimoto’s thyroiditis status were not significantly associated with LLNM ($P > 0.05$). Tumor location in the middle third of the thyroid gland conferred a high risk for LLNM. However, multivariate analysis identified only CLNM and recurrence as independent predictors for LLNM in patients who underwent follow-up for 40 to 72 months (Table 4).

\textbf{Correlation of clinicopathologic characteristics and \textit{BRAF}^{V600E} mutation}

Among the 1,587 patients, \textit{BRAF}^{V600E} mutation was detected in 299 patients with a frequency of 83.3\% (249/299). Univariate analysis showed that CLNM, LLNM, multifocality, and extrathyroidal extension were not significantly associated with \textit{BRAF}^{V600E} mutation. Among patients who underwent follow-up for 40 to 72 months, recurrence was not significantly associated with \textit{BRAF}^{V600E} (Table 5).

\textbf{Complications, follow-up, and recurrence}

Recurrent laryngeal nerve injury occurred in 14 patients...
among these, owing to direct tumor invasion, 8 patients underwent shaving procedures or intentional resection of the recurrent laryngeal nerve resulting in permanent vocal fold paralysis, while the injury in the other 6 patients was temporary. Of the 1,587 patients, 386 (24.3%) suffered postoperative hypocalcemia requiring calcium supplementation, and 4 (0.3%) experienced permanent hypocalcemia. Four patients developed a postoperative chylous fistula, and 1 patient required reoperation on the same day owing to postoperative bleeding.

Postsurgical clinical examinations were performed every 6 months; these included cervical US and serum thyroid

| Characteristics                  | Case n = 1,587 (%) | CLNM+/-% | LLNM+/-% |
|----------------------------------|--------------------|----------|----------|
| Gender                           |                    |          |          |
| Female                           | 1251 (78.8)        | 351/900 (28.1) | 53/1198 (4.2) |
| Male                             | 336 (21.2)         | 140/196 (41.7) | 20/316 (6.0) |
| Age, mean±SD (years)             | 45.7±9.4           |          |          |
| < 45                             | 726 (45.7)         | 259/467 (35.7) | 40/686 (5.5) |
| ≥ 45                             | 861 (54.3)         | 232/629 (26.9) | 33/828 (3.8) |
| PTMC with HT                     |                    |          |          |
| Yes                              | 333 (21.0)         | 105/228 (31.5) | 18/315 (5.4) |
| No                               | 1254 (79.0)        | 386/868 (30.8) | 55/1199 (4.4) |
| Tumor size, mean±SD (mm)         | 5.9±2.5            |          |          |
| > 6                              | 586 (36.9)         | 256/330 (43.7) | 45/541 (7.7) |
| ≤ 6                              | 1001 (63.1)        | 235/766 (23.5) | 28/973 (2.8) |
| Extrathyroidal extension         |                    |          |          |
| Yes                              | 1039 (65.5)        | 372/667 (35.8) | 63/976 (6.1) |
| No                               | 548 (34.5)         | 119/429 (21.7) | 10/538 (1.8) |
| Tumor location                   |                    |          |          |
| Multifocal lesion                | 573 (36.1)         | 237/336 (41.4) | 44/529 (7.7) |
| Solitary lesion                  | 1014 (63.9)        | 266/748 (26.2) | 29/985 (2.9) |
| Upper third                      | 312 (30.8)         | 72/240 (23.1) | 15/297 (4.8) |
| Middle third                     | 268 (26.4)         | 62/206 (23.1) | 3/265 (1.1) |
| Lower third                      | 407 (40.1)         | 126/281 (31.0) | 11/396 (2.7) |
| Isthmus                          | 27 (2.7)           | 6/21 (22.2) | 0/27 (0) |
| Bilateralism                     |                    |          |          |
| Yes                              | 378 (23.8)         | 177/201 (46.8) | 29/349 (7.7) |
| No                               | 1209 (76.2)        | 314/895 (26.0) | 44/1165 (3.6) |
| Subtype                          |                    |          |          |
| Classical                        | 1474 (92.9)        | 450/1024 (30.5) | 68/1406 (4.6) |
| Follicular variant               | 102 (6.4)          | 36/66 (35.3) | 5/97 (5.0) |
| Hürthle cell variant             | 11 (0.7)           | 5/6 (45.5) | 0/11 (0) |

PTMC: papillary thyroid microcarcinoma; HT: Hashimotos thyroiditis; CLNM: Central lymph node metastasis; LLNM: Lateral neck lymph node metastasis; +, Positive; -, Negative.
stimulating hormone and thyroglobulin levels. The mean follow-up duration was 56 months (range, 40–72 months), and 121 patients were lost to follow-up. During the follow-up period, 16 patients experienced recurrence in the central cervical compartment. Among 88 patients who had undergone lateral neck dissection, 3 patients (0.19%) suffered from LLNM: 2 and 1 experienced ipsilateral and contralateral neck recurrence, respectively. Among patients without LLNM at the time of initial treatment, 7 patients (0.44%) suffered regional recurrence: ipsilateral neck recurrence was

Table 3  Univariate and multivariate logistic regression for CLNM

| Independent variable                         | Univariate |          |          | Multivariate |          |          |
|---------------------------------------------|------------|----------|----------|--------------|----------|----------|
|                                             | OR (95% CI)| P        | OR (95% CI)| P            |          |          |
| Gender                                      |            |          |          |              |          |          |
| Female                                      | 1 (reference) | 0.000    | 1 (reference) | 0.000        |          |          |
| Male                                        | 1.832 (1.427–2.351) | 0.000    | 1.845 (1.419–2.399) | 0.000        |          |          |
| Age, years                                  |            |          |          |              |          |          |
| < 45                                        | 1 (reference) | 0.000    | 1 (reference) | 0.000        |          |          |
| ≥ 45                                        | 0.665 (0.537–0.824) | 0.000    | 0.624 (0.498–0.782) | 0.000        |          |          |
| PTMC with HT                                |            | 0.790    |          |              |          |          |
| Yes                                         | 1 (reference) | -        | -        |              |          |          |
| No                                          | 0.966 (0.744–1.253) | -        | -        |              |          |          |
| Tumor size (> 6 mm vs. ≤ 6 mm)              |            | 0.000    | 0.000    |              |          |          |
| ≤ 6 mm                                      | 1 (reference) | 0.000    | 1 (reference) | 0.000        |          |          |
| > 6 mm                                      | 2.529 (2.013–3.148) | 0.000    | 2.137 (1.694–2.697) | 0.000        |          |          |
| Extrathyroidal extension                    |            | 0.000    | 0.001    |              |          |          |
| Yes                                         | 1 (reference) | -        | 1 (reference) | -            |          |          |
| No                                          | 0.497 (0.391–0.632) | -        | 0.643 (0.498–0.782) | -            |          |          |
| Multifocal                                  |            | 0.000a   |          | 0.782        |          |          |
| Yes                                         | 1 (reference) | -        | 1 (reference) | -            |          |          |
| No                                          | 0.504 (0.406–0.627) | 0.000    | 0.953 (0.679–1338) | 0.000        |          |          |
| Bilateralism                                |            | 0.000    | 0.000    |              |          |          |
| Yes                                         | 1 (reference) | -        | 1 (reference) | -            |          |          |
| No                                          | 0.397 (0.312–0.504) | 0.000    | 0.495 (0.343–0.715) | 0.000        |          |          |
| Subtype                                     |            | 0.017    |          |              |          |          |
| Classical                                   | 1 (reference) | -        | 1 (reference) | -            |          |          |
| Follicular variant                          | 2.732 (1.253–5.957) | 0.009    | 2.101 (0.932–4.738) | 0.074        |          |          |
| Hürthle cell variant                       | 3.512 (0.585–21.098) | 0.143    | 1.926 (0.298–12.440) | 0.491        |          |          |
| Solitary lesion                             |            | 0.049b   |          |              |          |          |
| Upper third                                 | 1 (reference) | -        | -        |              |          |          |
| Middle third                                | 1.003 (0.681–1.478) | 1.000    | -        |              |          |          |
| Lower third                                 | 1.495 (1.067–2.093) | 0.023    | -        |              |          |          |
| Isthmus                                     | 5.675 (1.989–16.087) | 0.003    | -        |              |          |          |

aThe P-value means the difference between the group multifocal lesion and solitary lesions. bThe P-value means the difference among the upper third, top third, lower third, and isthmus in group of solitary lesion.

Cancer Biol Med Vol 16, No 1 February 2019
### Table 4  Univariate and multivariate logistic regression for LLNM

| Independent variable | Univariate | Multivariate |
|----------------------|------------|--------------|
|                      | OR (95%CI) | P            | OR (95%CI) | P          |
| Gender               |            |              |            |            |
| Female               | 1 (reference) | -            | -          | -          |
| Male                 | 1.403 (0.828–2.378) | -            | -          | -          |
| Age, years           |            |              |            |            |
| < 45                 | 1 (reference) | -            | -          | -          |
| ≥ 45                 | 0.684 (0.426–1.096) | -            | -          | -          |
| PTMC with HT         |            |              |            |            |
| Yes                  | 1 (reference) | -            | -          | -          |
| No                   | 0.803 (0.465–1.387) | -            | -          | -          |
| Tumor size (mm)      |            |              |            |            |
| ≤ 6                  | 1 (reference) | 1 (reference) | 1.392 (0.822–2.359) | 0.219 |
| > 6                  | 2.890 (1.783–4.687) | 1.392 (0.822–2.359) | 0.000     | 0.055     |
| Extrathyroidal extension |            |              |            |            |
| Yes                  | 1 (reference) | 1 (reference) | 1.392 (0.822–2.359) | 0.219 |
| No                   | 0.288 (0.147–0.566) | 0.496 (0.242–1.015) | 0.000     | 0.267     |
| Multifocal           |            |              |            |            |
| Yes                  | 1 (reference) | 1 (reference) | 1.392 (0.822–2.359) | 0.219 |
| No                   | 0.382 (0.235–0.622) | 0.668 (0.328–1.362) | 0.000     | 0.582     |
| Bilateralism         |            |              |            |            |
| Yes                  | 1 (reference) | 1 (reference) | 1.392 (0.822–2.359) | 0.219 |
| No                   | 0.455 (0.280–0.737) | 1.224 (0.595–2.519) | 0.002     | 0.582     |
| Subtype              |            |              |            |            |
| Classical            | 1 (reference) | -            | -          | -          |
| Follicular           | 1.646 (0.381–7.115) | 0.808 | -          | -          |
| Hürthle cell variant | 1.051 (1.038–1.063) | 1.000 | -          | -          |
| Solitary letion      |            |              |            |            |
| Upper third          | 1 (reference) | -            | -          | -          |
| Middle third         | 0.224 (0.064–0.783) | 0.014 | -          | -          |
| Lower third          | 0.550 (0.249–1.215) | 0.159 | -          | -          |
| Isthmus              | 1.051 (1.025–1.077) | 0.619 | -          | -          |
| CLNM                 |            |              |            |            |
| Negative             | 1 (reference) | -            | -          | -          |
| Positive             | 35.077 (14.048–87.587) | 29.354 (11.631–74.084) | 0.000     | 0.000     |
| Recurrence           |            |              |            |            |
| Yes                  | 1 (reference) | -            | -          | -          |
| No                   | 30.051 (12.458–80.551) | 25.254 (10.352–66.217) | 0.000     | 0.000     |
found in 4 patients, contralateral neck recurrence in 1, and bilateral neck recurrence in 2. Regional recurrence was frequent at levels III, IV, and II. Among 1,209 patients who did not undergo total thyroidectomy, 12 (0.99%) experienced malignant recurrence in the contralateral lobe. At the data cutoff point, no patient demonstrated distant metastasis. During the follow-up period, 2 patients died from adrenal insufficiency and pneumonia, and another died of heart failure. None of the patients died of PTMC.

**Discussion**

In this retrospective study, we evaluated the risk factors for CLNM and LLNM in 1,587 patients with PTMC. In previous reports, the prevalence of CLNM ranged from 24.1% to 64.1%2-3, and that for LLNM ranged from 3.7% to 44.5%2. In the present study, the prevalence of CLNM and LLNM was 30.9% (491 of 1,587) and 4.6% (73 of 1,587), respectively. There were 19 patients (19 of 73) with skip metastases, meaning LLNM without CLNM.

In the present study, we used univariate and multivariate logistic regression analyses to evaluate risk factors for cervical LNM. Consistent with the results of previous reports, we found that male gender, age less than 45 years, extrathyroidal extension, and bilateralism were independent risk factors for CLNM14-18. Multifocality was not an independent predictor of CLNM, although significance was demonstrated on univariate analysis.

Tumor size is considered to be an essential prognostic factor in patients with PTMC19. Although the majority of previous studies used a tumor size of 5 mm as the size threshold20-23, we assessed thresholds greater than 4 mm, 5 mm, 6 mm, 7 mm, and 8 mm by ROC curve analysis, and found that primary tumor size (> 6 mm) was significantly correlated with CLNM. Extrathyroidal extension was an evaluated risk factor for CLNM22,24. However, the diagnosis of extrathyroidal extension is subjective and controversial as there is not a well-defined true capsule in the thyroid gland. The thyroid capsule is usually made up of inconspicuous thin fibrous tissues and contains a variable amount of skeletal muscle, blood vessels, and adipose tissue. In the present study, most cases of PTMC with extrathyroidal extension exhibited extension to the perithyroid soft tissue, such as adipose tissue, rather than to the sternothyroid muscle. In this study, 1,039 (65.5%) patients showed extrathyroidal extension, as we selected intrathyroidal areas with low-risk thyroid carcinoma for observation rather than surgery.

Furthermore, the present study showed that tumor size greater than 6 mm, extrathyroidal extension, multifocality, bilateralism, and CLNM were statistically significant factors for LLNM, and CLNM was an independent risk factor. Although CLNM is not significantly associated with disease-free survival in PTMC25-27, this outcome can be strongly associated with LLNM.

| Parameter | Case (n=299) | BRAF V600E mutation (n=249) | BRAF V600E wild-type (n=50) | P  |
|-----------|-------------|-----------------------------|----------------------------|----|
| CLNM      |             |                             |                            |    |
| Positive  | 140 (46.8)  | 113 (80.7)                  | 27 (19.3)                  | 0.265 |
| Negative  | 159 (53.2)  | 136 (85.5)                  | 23 (14.5)                  |    |
| Multifocal|             |                             |                            |    |
| Yes       | 143 (47.8)  | 122 (85.3)                  | 21 (14.7)                  | 0.366 |
| No        | 156 (52.2)  | 127 (81.4)                  | 29 (18.6)                  |    |
| Extrathyroidal extension | | | | |
| Yes       | 233 (77.9)  | 192 (82.4)                  | 41 (17.6)                  | 0.447 |
| No        | 66 (22.1)   | 57 (86.4)                   | 9 (13.6)                   |    |
| LLNM      |             |                             |                            |    |
| Positive  | 23 (7.7)    | 22 (95.7)                   | 1 (4.3)                    | 0.075 |
| Negative  | 276 (92.3)  | 227 (82.2)                  | 49 (17.8)                  |    |
| Recurrence|             |                             |                            |    |
| No        | 283 (94.6)  | 234 (82.7)                  | 49 (17.3)                  | 0.088 |
| Yes       | 16 (5.4)    | 15 (93.8)                   | 1 (6.2)                    |    |
The connection between tumor location and LNM in patients with PTMC remains controversial. Wada et al. first reported that the location of PTMC may be related to CLNM and LLNM, although the differences were not statistically significant. Xiang et al. found a correlation between PTMC located in the middle third of the thyroid gland with both CLNM and LLNM. In contrast, Zhang et al. showed that location of PTMC in the upper third of the thyroid conferred a lower risk for CLNM and a higher risk for LLNM. In the present study, we found that tumor location in the lower third of the thyroid gland and the isthmus was strongly associated with CLNM, whereas tumor location in the middle third was correlated with LLNM.

The \(BRAF^{V600E}\) mutation, which occurs in about 29%–60% of PTC, has been identified as the most common genetic change in PTC. These mutations activate the RAS/RAF/mitogen-activated protein kinase pathway and cause the malignant proliferation of cells. Previous observations have indicated that the \(BRAF^{V600E}\) mutation is correlated with highly aggressive factors, such as advanced stage of disease, extrathyroidal extension, and nodal metastasis in PTC. The \(BRAF^{V600E}\) mutational status of highly aggressive PTMC was analyzed by Lee et al. who discovered that the rate of \(BRAF^{V600E}\) mutation in patients with penetration of the capsule was higher than the rate in those without. The authors also found that mutations occurred in 50% of T3 or T4 stage tumors, meaning that the presence of \(BRAF^{V600E}\) mutation can predict the existence of extrathyroidal metastasis. Moreover, the \(BRAF^{V600E}\) mutation was discovered more commonly in highly aggressive subtypes, such as tall cell PTMC, indicating that \(BRAF^{V600E}\) mutational status is significantly associated with poor tumor behavior. \(BRAF^{V600E}\) is also observed in PTMC, and the mutation may thus be an early event in tumor development, perhaps facilitating the acquisition of secondary genetic events through induction of genomic instability. However, unlike the findings of previous studies, Sun et al. observed that \(BRAF^{V600E}\) mutation displayed a weakly negative association with PTMC neck and distant metastasis in a group of 101 patients. In the present study, we were unable to identify a significant correlation between \(BRAF^{V600E}\) mutation and clinicopathologic characteristics such as multifocality, neck metastasis, and extrathyroidal extension. Accordingly, it seems that \(BRAF^{V600E}\) mutation is not a prognostic factor for PTMC. In fact, most patients with PTMC have an extremely good prognosis following surgery. Large numbers of patients undergo very long-term follow-up, and it will be necessary to identify the clinical relevance of the \(BRAF^{V600E}\) mutation in PTMC. Despite the restrictions of the current study, our data also suggest that larger studies are warranted to determine the relationships between the \(BRAF^{V600E}\) mutation and clinical characteristics in patients with PTMC.

Although we analyzed a cohort of 1,587 patients with PTMC, there are nonetheless still several limitations in the present study. First, the incidence of LLNM was relatively low in our research sample, and patients who did not undergo LLND were regarded as negative. However, prophylactic LLND could only be performed in cases of LLNM proven by FNAB or with clinical suspicion on US. In fact, prophylactic LLND is not recommended in the American Thyroid Association guidelines. Nevertheless, data based on prophylactic LLND are more accurate and meaningful. In PTMC, however, the complications of LLND cannot be weighed against its questionable effect on recurrence and survival. Second, long-term follow-up was not performed in the current study. Third, the \(BRAF^{V600E}\) mutation analyses were performed in a relatively small number of patients (299); therefore, the rate of \(BRAF^{V600E}\) mutation may be underestimated, leading to the absence of a significant correlation between \(BRAF^{V600E}\) mutation and aggressive factors.

Conclusions

In conclusion, the present study showed that male sex, age less than 45 years, tumor size larger than 6 mm, presence of bilateralism, and extrathyroidal extension were all independent risk factors for CLNM. Moreover, larger primary tumor, extrathyroidal extension, multifocality, bilateralism, and CLNM were factors that conferred an increased risk of LLNM. Notably, the location of the tumor had an important association with cervical lymph node metastasis status in patients with a solitary primary tumor. Specifically, PTMC location in the lower third of the thyroid gland and the isthmus was associated with a higher risk of LLNM. In our studies including 299 patients, \(BRAF^{V600E}\) mutation was not significantly associated with prognostic factors in patients with PTMC.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81402392, 81472580, 81502322) and Tianjin Municipal Science and technology project (Grant No. 15JCQNJC12800 and 17YFZCSY00690).
Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. R. Lloyd, R. De Lellis, P. Heitz, et al. The International Agency for Research on Cancer. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press International; 2004.

2. Kwak JY, Kim EK, Kim MJ, Son EJ, Chung WY, Park CS, et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol. 2009; 16: 1348-55.

3. Yin XJ, Liu CP, Guo YW, Li XY, Shen N, Zhao XW, Yu P, Wang S, Liu ZM. Influence of tumor extent on central lymph node metastasis in solitary papillary thyroid microcarcinomas: a retrospective study of 1092 patients. World J Surg Oncol. 2017; 15: 133-8.

4. Chow SM, Law SCK, Chan JKC, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid: Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003; 98: 31-40.

5. Ito Y, Tomoda C, Urushino T, Takamura Y, Miya A, Kobayashi K, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg. 2006; 30: 91-9.

6. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008; 15: 191-205.

7. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008; 93: 611-8.

8. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAF(V600E) mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012; 36: 310-7.

9. Choi SY, Park H, Kang MK, Lee DK, Lee DK, Lee HS, et al. The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol. 2013; 11: 291.

10. Kim SK, Park J, Woo JW, Lee JH, Choe JH, Kim JH, et al. Predictive factors for lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 2016; 23: 2866-73.

11. Park JP, Roh JL, Lee JH, Baek JH, Gong G, Cho KJ, et al. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma. Am J Surg. 2014; 208: 412-8.

12. Yang YL, Chen CZ, Chen ZM, Jiang JC, Chen YZ, Jin LP, et al. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2014; 81: 282-8.

13. Xu YN, Xu L, Wang JD. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res. 2018; 221: 128-34.

14. Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012; 97: 1250-7.

15. Malandrino P, Pellegriti G, Attard M, Violà MA, Giordano C, Sciacc A, et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab. 2013; 98: 1427-34.

16. Cho JK, Kim JY, Jeong CY, Jung EJ, Park ST, Jeong SH, et al. Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age. J Korean Surg Soc. 2012; 82: 281-7.

17. Ito Y, Miyazaki A, Ikura M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014; 24: 27-34.

18. Ji QH, Zhang L, Zhu YX, Huang CP. Long-term impact of initial surgical and medical therapy on young patients with papillary thyroid cancer and bilateral cervical metastases. Chin Med J. 2008; 121: 63-6.

19. Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006; 91: 2171-8.

20. Kim E, Choi JY, Koo DH, Lee KE, Youn YK. Differences in the characteristics of papillary thyroid microcarcinoma ≤ 5 mm and > 5 mm in diameter. Head Neck. 2015; 37: 694-7.

21. Vasileiadis I, Karakostas E, Charitoudis G, Stavrianaki A, Kapetanakis S, Kouraklis G, et al. Papillary thyroid microcarcinoma: clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest. 2012; 42: 657-64.

22. Lombardi CP, Bellantone R, De Crea C, Paladino NC, Fadda G, Salvatori M, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010; 34: 1214-21.

23. Haymart MR, Cayo M, Chen H. Papillary thyroid microcarcinomas: big decisions for a small tumor. Ann Surg Oncol. 2009; 16: 3132-9.

24. Yamashita H, Noguchi S, Murakami N, Toda M, Uchino S, Watanabe S, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999; 86: 842-9.

25. Yu XL, Song XJ, Sun WH, Zhao SH, Zhao JJ, Wang YJ. Independent risk factors predicting central lymph node metastasis in papillary thyroid microcarcinoma. Horm Metab Res. 2017; 49: 201-7.

26. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008; 144: 980-8.

27. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K,
Matsuzaka F, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007; 31: 2085-91.

28. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003; 237: 399-407.

29. Xiang DP, Xie LQ, Xu YL, Li ZY, Hong YR, Wang P. Papillary thyroid microcarcinomas located at the middle part of the middle third of the thyroid gland correlates with the presence of neck metastasis. Surgery. 2015; 157: 526-33.

30. Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey III TJ. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid. 2009; 19: 473-7.

31. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the \textit{BRAF} gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004; 45: 818-21.

32. Lee X, Gao M, Ji YF, Yu Y, Feng Y, Li YG, et al. Analysis of differential \textit{BRAF}V600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009; 16: 240-5.

33. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, et al. Clinicopathologic implications of the \textit{BRAF}V600E mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid. 2013; 23: 1423-30.

34. Kebebew E, Weng JL, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of \textit{BRAF} mutation in thyroid cancer. Ann Surg. 2007; 246: 466-71.

35. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, et al. Analysis of differential \textit{BRAF}V600E mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer. 2006; 107: 1831-8.

36. Seokho Yoon, Young-Sil An, Su Lee, Eu So, Jang-Hee Kim, Yoon-Sok Chung, Joon-Kee Yoon. Relation Between F-18 FDG Uptake of PET/CT and \textit{BRAF}V600E Mutation in Papillary Thyroid Cancer. Medicine (Baltimore). 2015; 94: c2063.

37. Gao M, Ge MH, Ji QH, Cheng RC, Lu HK, Guan HX, et al. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. Cancer Biol Med. 2017; 14: 203-11.

38. Ming Gao, Minghua Ge, Qinghai Ji, Ruochuan Cheng, Hankui Lu, Haixia Guan et al. 2017 Chinese expert consensus on the clinical application of serum marker for thyroid cancer. Cancer Biol Med. 2018; 15: 468-77.

Cite this article as: Zheng X, Peng C, Gao M, Zhi J, Hou X, Zhao J, et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients. Cancer Biol Med. 2019; 16: 121-30. doi: 10.20892/j.issn.2095-3941.2018.0125